Roger Adsett Sells 45,605 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 45,605 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $3,689,444.50. Following the completion of the transaction, the chief operating officer now owns 189,157 shares in the company, valued at approximately $15,302,801.30. This trade represents a 19.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total value of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total value of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $0.83 during midday trading on Friday, hitting $79.95. The stock had a trading volume of 1,690,520 shares, compared to its average volume of 1,955,787. The company’s 50-day moving average price is $72.79 and its 200-day moving average price is $73.10. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on INSM shares. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Guggenheim boosted their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC boosted its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC bought a new position in shares of Insmed during the third quarter valued at $30,000. GAMMA Investing LLC raised its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter worth $47,000. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.